Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2010 1
2011 2
2012 3
2013 4
2014 6
2015 6
2016 11
2017 11
2018 11
2019 15
2020 25
2021 28
2022 19
2023 20
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Results by year

Filters applied: . Clear all
Page 1
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study.
Decaux O, Fontan J, Perrot A, Karlin L, Touzeau C, Schulmann S, Manier S, Belhadj K, Trebouet A, Zunic P, Schiano De Colella JM, Castel B, Van De Wyngaert Z, Pica GM, Tiab M, Kuhnowski F, Bouketouche M, Rigaudeau S, Benramdane R, Tekle C, Lafore R, Gaucher M, Corre J, Leleu X. Decaux O, et al. Among authors: touzeau c. Eur J Haematol. 2024 May 7. doi: 10.1111/ejh.14225. Online ahead of print. Eur J Haematol. 2024. PMID: 38712850
Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study on the behalf of G2I and Intergroupe Francophone du Myélome.
Jourdes A, Cellerin E, Touzeau C, Harel S, Denis B, Escure G, Faure E, Jamard S, Danion F, Sonntag C, Ader F, Karlin L, Soueges S, Cazelles C, de La Porte des Vaux C, Frenzel L, Lanternier F, Brousse X, Cazaubiel T, Berger P, Collignon A, Blot M, Pieragostini A, Charles M, Chaleteix C, Redor A, Roland V, Cartau T, Macro M, Chalopin T, Vallet N, Perrot A, Martin-Blondel G; G2I and the IFM networks. Jourdes A, et al. Among authors: touzeau c. Clin Microbiol Infect. 2024 Mar 1:S1198-743X(24)00098-3. doi: 10.1016/j.cmi.2024.02.023. Online ahead of print. Clin Microbiol Infect. 2024. PMID: 38432433 Free article.
Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study.
Laribi K, Leleu X, Texier N, Germain R, Touzeau C, Hammoud M, Payssot A, Schulmann S, Le Calloch R, Trebouet A, Chaoui D, David S, Benbrahim O, Benramdane R, Charvet-Rumpler A, Jadeau C, Rouanet E, Decaux O, Perrot A. Laribi K, et al. Among authors: touzeau c. EJHaem. 2023 Dec 13;5(1):55-60. doi: 10.1002/jha2.828. eCollection 2024 Feb. EJHaem. 2023. PMID: 38406520 Free PMC article.
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.
Jullien M, Guillaume T, Le Bourgeois A, Peterlin P, Garnier A, Eveillard M, Le Bris Y, Bouzy S, Tessoulin B, Gastinne T, Dubruille V, Touzeau C, Mahé B, Blin N, Lok A, Vantyghem S, Sortais C, Antier C, Moreau P, Scotet E, Béné MC, Chevallier P. Jullien M, et al. Among authors: touzeau c. Am J Hematol. 2024 Mar;99(3):350-359. doi: 10.1002/ajh.27191. Epub 2024 Jan 2. Am J Hematol. 2024. PMID: 38165016 Clinical Trial.
A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
Durand R, Descamps G, Bellanger C, Dousset C, Maïga S, Alberge JB, Derrien J, Cruard J, Minvielle S, Lilli NL, Godon C, Le Bris Y, Tessoulin B, Amiot M, Gomez-Bougie P, Touzeau C, Moreau P, Chiron D, Moreau-Aubry A, Pellat-Deceunynck C. Durand R, et al. Among authors: touzeau c. Blood. 2024 Mar 28;143(13):1242-1258. doi: 10.1182/blood.2023021581. Blood. 2024. PMID: 38096363
Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group.
Frenzel L, Decaux O, Macro M, Belhadj-Merzoug K, Manier S, Touzeau C, Leleu X, Frère C, Lecompte T, Perrot A, Avet-Loiseau H, Moreau P, Chalayer E. Frenzel L, et al. Among authors: touzeau c. Thromb Res. 2024 Jan;233:153-164. doi: 10.1016/j.thromres.2023.11.021. Epub 2023 Dec 2. Thromb Res. 2024. PMID: 38064842 Free article.
Quad-class exposed/refractory myeloma is associated with short survival.
Piron B, Costes-Tertrais D, Gastinne T, Fourmont AM, Dubruille V, Blin N, Moreau P, Touzeau C, Tessoulin B. Piron B, et al. Among authors: touzeau c. Br J Haematol. 2024 Jan;204(1):186-190. doi: 10.1111/bjh.19148. Epub 2023 Oct 13. Br J Haematol. 2024. PMID: 37833834
Author Correction: Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation.
Derrien J, Gastineau S, Frigout A, Giordano N, Cherkaoui M, Gaborit V, Boinon R, Douillard E, Devic M, Magrangeas F, Moreau P, Minvielle S, Touzeau C, Letouzé E. Derrien J, et al. Among authors: touzeau c. Nat Cancer. 2023 Nov;4(11):1610. doi: 10.1038/s43018-023-00646-4. Nat Cancer. 2023. PMID: 37684528 No abstract available.
146 results